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Abstract
Malaria poses an exceptionally complex problem for providers of travel medicine services. Perceived high risk of exposure
during travel typically prompts prescribing protective antimalarial drugs. Suppressive chemoprophylactic agents have
dominated strategy for that practice for over 70 years. This broad class of therapeutic agents kills parasites after they
emerge from the liver and attempt development in red blood cells. The dominance of suppressive chemoprophylaxis
in travel medicine stems largely from the view of Plasmodium falciparum as the utmost threat to the patient – these
drugs are poorly suited to preventing Plasmodium vivax and Plasmodium ovale due to inactivity against the latent liver
stages of these species not produced by P. falciparum. Those hypnozoites awaken to cause multiple clinical attacks called
relapses in the months following infection. Causal prophylactic agents kill parasites as they attempt development in
hepatic cells. The only drug proven effective for causal prophylaxis against P. vivax is primaquine. That drug is not widely
recommended for primary prophylaxis for travelers despite preventing both primary attacks of all the plasmodia and
relapses of P. vivax. The long-held perception of P. vivax as causing a benign malaria in part explains the dominance of
suppressive chemoprophylaxis strategies poorly suited to its prevention. Recent evidence from both travelers and patients
hospitalized in endemic areas reveals P. vivax as a pernicious clinical threat capable of progression to severe
disease syndromes associated with fatal outcomes. Effective prevention of clinical attacks of vivax malaria
following exposure during travel requires primary causal prophylaxis or post-travel presumptive anti-relapse
therapy following suppressive prophylaxis.
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Global risk
The malaria caused by Plasmodium vivax occurs wher-
ever there is Plasmodium falciparum with few excep-
tions (e.g., Haiti), and sometime occurs as the sole
malaria present (e.g., the Korean Peninsula). Although
much of Africa has been thought virtually free of P.
vivax, it is nonetheless relatively common all along the
northern Sahel, the Horn, and on Madagascar [1], and
travelers to central, western, and southern sub-Saharan
Africa acquire P. vivax despite dominance of supposedly
protective erythrocyte surface Duffy factor negativity in
those populations [1, 2]. Among 618 cases of P. vivax in
European travelers reported between 1999 and 2003,
21% were acquired in western, central and southern
areas of Africa where P. vivax is not prevalent [1, 2].
Likewise, among 176 repatriated patients diagnosed with
P. vivax, 32% acquired the infection in sub-Saharan
Africa [3]. Recent evidence suggests P. vivax may utilize
erythrocyte surface molecules for invasion other than
Duffy factor [4]. Transmission without detectable preva-
lence was suggested by the finding of 13% of residents of
the Congo in west central Africa being positive for anti-
bodies specific to P. vivax sporozoites [5]. About 2.8
billion people live at risk of P. vivax with the majority of
infections occurring in South and Southeast Asia [6].
This species dominates as the cause of most malaria
infections in endemic Central and South America.
Virtually everywhere malaria is transmitted, P. vivax is
present [7] and must be considered in advice to patients
visiting those areas.
Virulence
Appropriate caution demands awareness of P. vivax as
an often-inherently virulent parasite capable of causing
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severe malaria syndromes associated with death [8]. Al-
though virulence is known to vary with P. vivax strains,
none occurring today have been demonstrated to rarely
progress to severe states of illness. In hospital-based
studies from all across the globe, dangerous virulence
appears to be common, with severe anemia and
thrombocytopenia, respiratory distress, hepatic dysfunc-
tion, kidney injury and renal failure, seizures and coma,
and circulatory collapse sometime occurring with acute
P. vivax malaria [9]. During the 1920s and 1930s, pa-
tients with neurosyphilis were treated with induced
attacks of P. vivax malaria, and 5–15% of otherwise rela-
tively healthy patients did not survive those attacks,
most dying at the sixth paroxysm [8]. A meta-analysis of
risk of defined severe malaria syndromes among patients
living in endemic areas and admitted to hospital with a
primary diagnosis of vivax or falciparum malaria showed
equal risk between these species (OR = 0.94; 95%CI, 0.2–
4.4) [10]. Similar analyses showed slightly lower risk of
death with vivax relative to falciparum malaria (OR =
0.64; 95%CI, 0.5–0.8) among hospitalized patients [11].
Among patients admitted to American hospitals, those
with a diagnosis of P. falciparum were more likely to be
classified as severely ill relative to P. vivax (OR = 7.7;
6.3–8.8), but among the severely ill risk of death be-
tween the species did not differ significantly (OR = 1.6;
0.8–3.2) [12]. These findings also emerged with Plasmo-
dium ovale malaria for severe illness (OR = 5.0; 3.1–8.0)
and death with severe illness (OR = 0.84; 0.2–3.7) relative
to P. falciparum among those patients treated in the
United States [12]. Patients diagnosed with P. vivax or P.
ovale should be considered at risk of progression to se-
vere disease syndromes as dangerous as those associated
with a diagnosis of P. falciparum.
The relapse problem
A single infectious bite by an anopheline mosquito bear-
ing sporozoites of P. falciparum results in a single attack
of malaria, whereas the same bearing P. vivax often
yields five or more attacks within a year or two. The risk,
timing, and number of relapses vary according to origin
of infection [13]. Temperate strains and those from the
Indian sub-continent are typically less likely to relapse
(about 30%) and do so about 6–8 months following in-
fection, but then also cause multiple attacks (3 may be
typical). Strains of P. vivax from Southeast Asia and
Oceania very often (>80% of patients) relapse within
3 weeks of patency of the primary attack and with mul-
tiple attacks to follow at approximately 2-month inter-
vals [14]. In two cohorts of Indonesian travelers totaling
1182 people, 382 suffered P. vivax attacks within
6 months after return from travel; 80 of those were not
treated with primaquine and 79% relapsed, most within
3 months of patency [15, 16]. Among 207 P. vivax
patients in Thailand treated with chloroquine alone, 79%
had recurrent parasitemia within 2 months [17]. At least
some South American strains of P. vivax behave simi-
larly [18]. Schwartz and colleagues [19] evaluated 300
cases of malaria among Israeli travelers, and 134 (45%)
occurred more than 2 months following return from
travel, with P. vivax contributing 129 (96%) of those at-
tacks. Those authors considered 81% of those patients as
having followed their suppressive chemoprophylaxis reg-
imens in accordance with national guidelines. Travelers
provided suppressive chemoprophylaxis and exposed to
P. vivax but not treated with primaquine at termination
of travel face high risk of clinical attacks [20].
Suppressive chemoprophylaxis, PART and G6PD
deficiency
Suppressive chemoprophylaxis does not impact the la-
tent liver forms of P. vivax. Protection against late at-
tacks requires presumptive anti-relapse therapy (PART)
with primaquine (0.5 mg/kg daily for 14 days) after
travel. Not all authoritative guidelines recommend PART
after travel under suppressive chemoprophylaxis [21–27]
and some recommend against it [24]. Among those that
do recommend post-travel PART, it is reserved for pa-
tients exposed to high risk of P. vivax for relatively pro-
longed periods [21, 26]. The apparent reluctance to
recommend prescribing PART may stem from the
relative difficulty of safely and effectively doing so. Some
view the 14 daily doses as onerous, and primaquine
causes a potentially threatening hemolytic anemia in
patients having an inborn deficiency of the enzyme
glucose-6-phosphate dehydrogenase (G6PD) [28] neces-
sitating laboratory screening time and costs.
Safe administration of this regimen of primaquine in-
deed demands affirming G6PD normal status, and ad-
herence to the two weeks of dosing may be viewed as
inconvenient or improbable. Nonetheless, if patients and
providers alike understand the potentially threatening
nature of acute attacks by P. vivax, G6PD screening and
good adherence may be viewed as less problematic than
with a supposedly benign and not threatening illness.
Further, recently available point-of-care G6PD diagnos-
tics may ease the inconvenience and cost of that screen-
ing [29]. The U.S. Food and Drug Administration
approved at least one such screening kit [30].
Users of qualitative G6PD screening kits of any type
should be aware of the insensitivity to G6PD levels
above 30% of normal enzyme activity [31]. This often
occurs among female heterozygotes for this X-linked
trait having red blood cell populations mosaic for the de-
ficiency at any frequency between 0 and 100% due to the
phenomenon of lyonization during embryonic develop-
ment. Females screened as “normal” may thus be at risk
of up to 70% hemolytic loss of red blood cells with
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primaquine dosing [11]. Female travelers may require a
quantitative laboratory assessment of G6PD status.
There is no firmly established quantitative cut off of
G6PD activity for safety with primaquine, but >70% of
normal would exclude most heterozygotes and be un-
likely to seriously threaten those included.
Causal chemoprophylaxis
One of the most widely prescribed drugs for malaria
chemoprophylaxis is Malarone® (GlaxoSmithKline UK,
atovaquone-proguanil). The atovaquone component of
this formulation showed causal prophylactic activity
against P. falciparum, i.e., killed developing liver stages
[32]. However, this activity may be absent or weak
against P. vivax liver stages [33, 34], although some evi-
dence suggests otherwise [35]. This important unre-
solved question requires clarification. Primaquine is the
only available drug proven to arrest the development of
both primary tissue schizonts and hypnozoites [36].
When taken as 0.5 mg/kg daily during exposure to infec-
tious anophelines, primaquine prevented primary attacks
of both P. falciparum and P. vivax with good efficacy
(>90%), in addition to preventing the formation of hyp-
nozoites of P. vivax [36, 37].
Confusion regarding the term causal prophylaxis
merits some clarification here. Some authorities explain
that causal prophylaxis impacts only developing tissue
schizonts in the liver and does not impact hypnozoites
[24]. While it is true that some drugs can prevent the
formation of hypnozoites while being unable to kill
formed hypnozoites [38], in practice causal prophylaxis
begins in travelers free of infection. In the specific in-
stance of primaquine as causal prophylaxis, it prevents
the formation of both tissue schizonts and hypnozoites,
like the experimental drug PI4 kinase [38]. It is thus in-
correct to infer that causal prophylactics will not prevent
the seeding of the liver with hypnozoites. Primaquine
prophylaxis, unlike PI4 kinase [38], also happens to kill
formed hypnozoites in patients infected without causal
prophylaxis, i.e., as post-suppressive prophylaxis PART
or radical cure of acute vivax malaria.
Primaquine as primary causal prophylaxis offers sev-
eral distinct advantages. No pre-travel dosing is neces-
sary, and post-travel dosing of a few days suffices. The
regimen of course also abrogates the need for post-travel
PART. These attributes give primaquine chemoprophy-
laxis great appeal for travelers departing on short notice
or only briefly exposed to risk (e.g., a week or so) whom
may otherwise endure several weeks of pre- and post-
travel dosing with a suppressive chemoprophylactic and
PART. Nonetheless, if P. vivax indeed occurs wherever
there is malaria risk, and the clinical necessity of
preventing relapses may be accepted, then primaquine
as primary prophylaxis may be considered as a viable
option for any traveler, regardless of destination or dur-
ation of exposure. The clinical trials of primaquine
prophylaxis dosed subjects daily for 3 to 12 months with
good safety and tolerance (when administered with a
snack or meal) and efficacy against P. vivax and P.
falciparum [36].
The principal shortcomings with primaquine for pri-
mary prophylaxis include the necessity of daily dosing,
G6PD screening, contraindications with pregnancy or
infancy, and emerging evidence of cytochrome P-450
isozyme 2D6 (CYP2D6) polymorphisms rendering
primaquine inactive in some patients [39, 40]. The fre-
quency of CYP2D6 alleles associated with therapeutic
failure of primaquine is not known and varies widely
among ethnic populations, but 1–10% may be a rea-
soned forecast [41]. Complete assurance of primaquine
activity may require ascertaining CYP2D6 genotype, a
relatively expensive and sophisticated laboratory analysis
with a complex and nuanced clinical interpretation.
Another potential pitfall with primaquine is its lack of
activity against the blood stages of P. falciparum, despite
good activity against the same of P. vivax. The traveller
experiencing a breakthrough of P. falciparum may not
be protected by on-going primaquine prophylaxis,
whereas a suppressive prophylactic regimen would per-
haps slow progression of the infection despite failure.
Finally, the label of primaquine does not include an
indication for primary prophylaxis, necessitating off-
label prescribing.
Travel medicine experts informing guidance on mal-
aria chemoprophylaxis have not put primaquine as pri-
mary causal prophylaxis forward as a recommended
option except as a last resort or for special circum-
stances (Table 1). Some of the pitfalls listed above likely
weighed in that deliberation. Acknowledging that no
regimen of chemoprophylaxis is without risk and poten-
tial pitfalls, the provider weighs the relevant risks and
benefits to each traveler in deciding upon appropriate
protection. That weighing should include primary at-
tacks and relapses of P. vivax as a potentially serious
threat to travelers visiting almost any malarious area.
Vivax malaria should not be considered a benign and in-
consequential risk. Primaquine as primary causal
prophylaxis or as PART following suppressive prophy-
laxis effectively deals with the problem of P. vivax
relapses after travel. Current guidelines deal poorly with
preventing those by the uniform primacy of suppressive
chemoprophylaxis strategy and weakness of recommen-
dations regarding post-travel PART in that strategy.
Ideal chemoprophylaxis
The ideal drug for preventing malaria in travelers would
exert both causal and suppressive activity with weekly or
longer interval dosing, not threaten G6PD deficient or
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pregnant patients, not be reliant upon appropriate cyto-
chrome P-450 phenotypes for good activity, and include the
indication in its approved label. No such drug is currently
available, although one in clinical development may more
closely approach this ideal than any others now available.
Tafenoquine is a primaquine-like 8-aminoquinoline under
development by GlaxoSmithKline (GSK, UK) and the
Medicines for Malaria Venture (MMV, Geneva) for radical
cure of P. vivax [42]. Earlier, the drug had been under devel-
opment by GSK and the U.S. Army as a chemoprophylactic
agent with good efficacy against P. falciparum and P. vivax
when administered monthly for up to 5 months [43]. Onset
of a mild reversible vortex keratopathy occurred in most
subjects of another trial dosed weekly for 6 months [44].
Tafenoquine shares the hemolytic toxicity problem of
primaquine [45] and its single dose with relatively long
elimination half-life elevates the importance of robust G6PD
screening in conjunction with intended clinical use. Depend-
ence upon CYP2D6 phenotypes for activity is not yet known
for tafenoquine. Despite these known or potential pitfalls,
should the development of tafenoquine for chemoprophy-
laxis resume and result in a labeled indication, it may well
offer a superior option for travelers exposed to P. vivax and
P. falciparum malarias.
Radical cure of Plasmodium vivax
Patients diagnosed with malaria caused by P. vivax re-
quire therapy that terminates the acute attack (blood
schizontocidal) and prevents subsequent attacks by
relapse (hypnozoitocidal). This treatment is called rad-
ical cure and several options for it may be considered
[46]. Many different regimens of primaquine therapy
have been recommended over the 60 years of its
availability as the only hypnozoitocide, but the 0.5 mg/
kg daily for 14 days is now widely considered preferred
among those [27, 47]. Many nations recommend
0.25 mg/kg daily for 14 days, but likely do so despite
relatively low efficacy [48] in order to mitigate risk of
harm due to poor access to G6PD screening.
Chloroquine-resistant P. vivax occurs globally but is
most common in areas of Southeast Asia and Oceania
[49]. Treatment of those infections necessitates use of
quinine or artemisinin-combined therapies (ACTs) with
primaquine for radical cure.
Although some authorities include a recommendation for
artemether-lumefantrine with primaquine for radical cure of
chloroquine-resistant P. vivax, only dihydroartemisinin-
piperaquine and artesunate-pyronaridine combined with
primaquine have been demonstrated as safe, well tolerated
and efficacious for radical cure in G6PD-normal non-
pregnant subjects [15, 16]. The dependence of primaquine
activity on CYP2D6 metabolism renders it vulnerable to
impeded efficacy by partner drugs that may inhibit CYP2D6
activity. Lumefantrine happens to be a moderately potent
CYP2D6 inhibitor and The Medical Letter [23] explicitly
warns against use of artemether-lumefantrine with drugs
that are metabolized by CYP2D6.
Evidence-based medical practice demands proof of
safety, tolerability, and efficacy with drugs used in tandem,
as in radical cure of P. vivax malaria. Blood schizontocides
may not be responsibly combined with primaquine with-
out such evidence [50]. The same will be true the hypno-
zoitocide tafenoquine following its aspired availability in
practice. A single dose of tafenoquine combined with
chloroquine for radical cure has shown good safety,
tolerability, and efficacy in G6PD-normal non-pregnant
research subjects infected by P. vivax [42]. The label of
tafenoquine would thus be very likely to narrowly specify
chloroquine as the partner blood schizontocide. Given the
rise of chloroquine-resistant P. vivax, tafenoquine would
inevitably be combined with artemisinin-combined ther-
apies. Doing so responsibly will require demonstrations of
safety, tolerability, and efficacy for each partner blood
schizontocide in radical cure.
Conclusions
Malaria caused by P. vivax occurs wherever malaria is
transmitted with very few exceptions. Despite long being
Table 1 Authoritative recommendations regarding primaquine for the prevention and treatment of P. vivax malaria
United States United Kingdom Canada International
Source U.S. government The Medical Letter U.K. government Canadian government World Health Organization
Primaquine as
Primary Prophylaxis







Only as an alternative
to suppressive options
Not recommended Only as an alternative
to suppressive options
None specified except for special
risk groups (infants, pregnant
women, vulnerable children in
seasonal high transmission)
Primaquine following
a diagnosis of P. vivax
Recommended Recommended Recommended Recommended Strongly recommended
Primaquine following
suppressive prophylaxis
Recommended No recommendation Not recommended Recommended for
high risk groups
No recommendation
References [21] [22, 23] [24, 25] [26] [27]
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perceived as an intrinsically benign species, evidence
now affirms this species as capable of progressing to se-
vere disease syndromes associated with fatal outcomes,
including in travelers. Effective prevention of P. vivax in
travelers is not achieved with the suppressive chemo-
prophylaxis strategies that dominate authoritative guid-
ance on preventing malaria in travelers. The latent
hypnozoites of this species are not affected by suppres-
sive chemoprophylaxis, and unless the exposed traveler
is prescribed post-exposure PART with primaquine, late
attacks by P. vivax may occur. Primary causal chemo-
prophylaxis using daily primaquine (0.5 mg/kg) during
exposure prevents primary attacks of P. falciparum and
P. vivax, and prevents relapses by the latter with good
safety, tolerability, and efficacy in G6PD normal non-
pregnant subjects (>90%), despite likely failures due to
relatively infrequent CYP2D6 inadequate metabolizer
phenotypes. Providers of travel medicine services should
consider the advantages and pitfalls of both suppressive
and causal prophylactic strategies in preventing attacks
of P. vivax now firmly linked to risk of poor clinical out-
comes. Both strategies apply primaquine, either as PART
or primary prophylaxis, respectively, and necessitates
coping with risk to G6PD-deficient or pregnant patients.
Likewise, travelers suffering acute attacks of P. vivax
should be considered at high risk of multiple recurrences
if they do not receive radical cure employing prima-
quine, the only therapeutic option at present. In all
facets of responsibly managing risk and illness of P.
vivax in travelers, primaquine is involved and providers
have to deal with the serious problem of its toxicity with
G6PD deficiency. This will remain especially true follow-
ing the anticipated registration and availability of tafeno-
quine as a single dose (with chloroquine) agent for
radical cure of P. vivax malaria.
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